Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Phathom Pharmaceuticals ( (PHAT) ) has provided an announcement.
On October 25, 2025, Phathom Pharmaceuticals announced the publication of additional analyses from its Phase 3 pHalcon-NERD-301 trial in the American Journal of Gastroenterology, highlighting the effectiveness of VOQUEZNA® (vonoprazan) tablets in treating nighttime symptoms of Non-Erosive Reflux Disease (NERD). The trial demonstrated that VOQUEZNA significantly improved the percentage of heartburn-free nights and was generally well tolerated, offering a promising alternative for patients who experience inadequate relief from existing treatments. This development could enhance Phathom’s positioning in the gastrointestinal treatment market by addressing a significant gap in current GERD therapies.
The most recent analyst rating on (PHAT) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals’ overall score reflects significant financial challenges, with ongoing losses and negative cash flows weighing heavily. Despite strong technical momentum and positive earnings call guidance, the negative valuation metrics and financial instability are major concerns. The company’s reliance on external financing and potential supply disruptions also pose risks.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
Phathom Pharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of novel treatments for gastrointestinal diseases. The company’s primary product, VOQUEZNA® (vonoprazan), targets conditions such as Non-Erosive Reflux Disease (NERD) and aims to address unmet needs in the market for effective nighttime GERD symptom relief.
Average Trading Volume: 1,164,013
Technical Sentiment Signal: Buy
Current Market Cap: $959.9M
For detailed information about PHAT stock, go to TipRanks’ Stock Analysis page.